The Aliaksei Pustavoitau Lab conducts research on models and mechanisms of impaired consciousness in patients who have suffered acute brain injury. Examples of our work include a study on the mechanisms of neurologic failure in critical illness and another on the use of intensivist-driven ultrasound at the PICU bedside. We also have a longstanding interest in patient safety and quality of care in the ICU setting.

Researchers in the David Thompson Lab examine the outcomes of patients treated in intensive care units (ICUs), patient safety efforts, quality improvement efforts, and multidisciplinary teamwork and safety curriculum development. We're taking part in a study aimed at reducing hospital-acquired infections among cardiovascular surgery patients. Our investigators also participated in a clinical research collaboration that saw an 81 percent reduction in bloodstream infections related to central lines.

We are interested in understanding how innate immune responses regulate lung health. Innate immunity involves ancient, and well-conserved mediators and their actions regulate the balance between homeostasis and pathogenesis. In the lungs, innate immunity play a critical role in response to environmental exposures such as allergen and ambient particulate matter. My lab focuses on how these exposures can promote aberrant mucosal responses that can drive the development of diseases like asthma.

The Timothy Niessen Lab studies patient outcomes in the ICU. We are particularly interested in the effects of sleep quality, delirium transitions and sedation on the improvement of intensive care patients. Our investigators also focus on the practices of internal medicine interns, studying the variability of hand washing hygiene, etiquette-based communication and time spent in direct and indirect patient care. We have also studied the onset of myelopathy as a result of B12 deficiency from long-term colchicine treatment and recreational nitrous oxide use.

Research conducted in the Todd Dorman Lab examines the use of informatics in intensive care settings as it relates to remote patient monitoring, safety and management strategies. Specific areas of interest include the surgical stress response; aminoglycoside antibiotics; fungal infections; renal failure; pharmacokinetic models of drug administration; and ICU triage and its impact on disaster preparedness.

Chronic rhinosinusitis (CRS) is a leading cause of morbidity globally and is the single most common self-reported chronic health condition and accounts for billions of dollars in health care costs and lost work days annually. Exposure to air pollutants is thought to be a critical modifier of CRS susceptibility. Despite marked reductions in air pollution levels in the United States, the fine particulate component of air pollution (PM2.5) and ultrafine pollutants secondary to traffic continue to remain a recalcitrant issue globally and in the United States. The Ramanathan Lab focuses on studying the role of air pollution (PM2.5) in CRS. In collaboration with scientists at the Bloomberg School of Public Health, we have utilized a state of the art air pollution exposure system to develop a novel mouse model of air pollution induced rhinosinusitis that mimics many of the features of CRS in humans. Our lab uses transgenic mouse models and novel immunologic/genomic techniques to study the mechanisms by which PM2.5 causes eosinophilic inflammation and sinonasal epithelial barrier dysfunction. We are also interested in the role of the antioxidant transcription factor, Nrf2, which has shown to stabilize the epithelial barrier and reduce eosinophilia in PM induced rhinosinusitis as a potential therapeutic target.

Research in the John Matthew Austin Lab explores health care performance measures, with a goal of improving patient care by enabling healthcare providers to view data about their performance, track patient outcomes and comply with best care practices. Our lab is currently working to develop performance measures for the ICU part, and we are part of The Leapfrog Group, an annual survey of U.S. hospitals that compares hospital performance on national measures of safety, quality and efficiency. Our research also explores the use of scientifically sound decision-support tools for guiding improvements in healthcare delivery systems.

The Peisong Gao Lab’s major focus is to understand the immunological and genetic regulation of allergic diseases. We have been involved in the identification of the genetic basis for atopic dermatitis and eczema herpeticum (ADEH) as part of the NIH Atopic Dermatitis and Vaccinia Network-Clinical Studies Consortium. Major projects in the Gao Lab include immunogenetic analysis of human response to allergen, identification of candidate genes for specific immune responsiveness to cockroach allergen, and epigenetics of food allergy (FA).

Research in the Alison E. Turnbull Lab focuses on patient-clinician interactions. We study decision-making processes for ICU patients and their families and focus on the long-term outcomes of ICU survivors. Additional research examines ways to improve end-of-life care for patients.

Work in the Sean Berenholtz Lab focuses on patient safety, ICU care, quality health care and evidence-based medicine. Two notable and successful projects include the National On The Cusp: Stop BSI project, which was implemented in 47 states with the goal of eliminating bloodstream infections, and the Agency for Healthcare Research and Quality (AHRQ)-funded Keystone ICU project, which improved communication and teamwork and reduced hospital-acquired infections in more than 100 ICUs in Michigan. One recent study focused on ventilator-associated pneumonia (VAP), one of the most common type of health care-associated infections in the ICU. Existing VAP prevention intervention bundles vary widely on the interventions, but our research team described a structured approach for developing a new VAP prevention bundle.